Barrett's oesophagus: how should we manage it?

Por Old, O J, Almond, L M, Barr, H
Publicado no Frontline Gastroenterol (2015)

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Por Ke, A, Barter, Z, Rowland‐Yeo, K, Almond, L
Publicado no CPT Pharmacometrics Syst Pharmacol (2016)

Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model

Por Marsousi, N, Daali, Y, Rudaz, S, Almond, L, Humphries, H, Desmeules, J, Samer, C F
Publicado no CPT Pharmacometrics Syst Pharmacol (2014)

Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs

Por Gaohua, L, Wedagedera, J, Small, BG, Almond, L, Romero, K, Hermann, D, Hanna, D, Jamei, M, Gardner, I
Publicado no CPT Pharmacometrics Syst Pharmacol (2015)